← All trials
NCT05699759
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 28, 2023
- Primary completion
- Dec 31, 2024
- Completion date
- Dec 31, 2024
- First posted
- Jan 26, 2023
- Last posted
- Dec 12, 2023
- Enrollment
- 5
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of KentuckyLead sponsor
- University of KentuckyOverall official - principal investigator
- University of KentuckySponsor investigator
- Inflammasome TherapeuticsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.